مقالات پذیرفته شده در سومین کنگره بین المللی زیست پزشکی
Challenges and opportunities of Gilteritinib in the treatment of acute myeloid leukemia over other tyrosine kinase inhibitors: A review Study
Challenges and opportunities of Gilteritinib in the treatment of acute myeloid leukemia over other tyrosine kinase inhibitors: A review Study
Alireza Aali Eiri Sofla,1,*
1. Student Research Committee , Urmia University of Medical Sciences , Urmia , Iran
Introduction: Introduction:
Acute myeloid leukemia is one of the most common cancers in the world. A mutation in the FLT3 gene induces acute myeloid leukemia due to the overproduction of myelocytes. Thus, according to scientific findings, by preventing the mutation of the relevant gene, the myelocyte proliferation can be suppressed indefinitely. Many drugs have been introduced in this field. We describe in this article the properties of such drugs; and investigate the superiority of Gilteritinib over other TKIs (Tyrosine Kinase Inhibitors).
Methods: Methods:
In this study we reviewed articles and indexed studies in various databases including Google Scholar, CDI, Pubmed, Scopus, Iran Medex and Iran Doc on the benefits of Gilteritinib over other TKIs. Among 200 articles related to the research topic, 30 articles were selected by purposive sampling.
Results: Results:
According to studies, Gilteritinib is a type of tyrosine kinase inhibitor (TKI), known as Xapata®, available as an edible product in the drug market, and can inhibit all three types of mutations FLT3-ITD / FLT3-D835Y / FLT3-ITD-D835Y. It also has less anti-kit-C activity, which has great importance in hematopoiesis. It also binds to and inhibits wild-type ALK (CD246 / Anaplastic Lymphoma Kinase) which is one of the features of this drug. The most important advantage of this drug is its anti-Axl activity.
Conclusion: Conclusion:
According to studies and articles, we concluded that Gilteritinib is more potent than other TKIs and also inhibits lower doses of EMLT in conventional doses, leading to less toxicity of the drug. Unlike other drugs which cause tolerance after a period of consumption, no noticeable tolerance has been observed in Gilteritinib due to antioxidant activity. This drug inhibits all three types of mutations that lead to MDL, therefore it has a wide range of response in comparison to other TKIs. Unfortunately it has some disadvantages like pancreatitis and changes in the electrical activity of heart called QTc prolongation that can be life-threating for consumers.